Sema4

May 13, 2022

Sema4 Bullish on Future Following GeneDx Acquisition, Corporate Restructuring
Premium

May 12, 2022

Sema4 Q1 Revenues Decline 16 Percent

May 6, 2022

In Brief This Week: FDA, Sema4, Veracyte, Trinity Biotech; Binx Health, More

Mar 15, 2022

Sema4 Q4 Revenues Decline 10 Percent

Jan 20, 2022

Sema4 to Embrace Co-CEO Model After $623M Acquisition of GeneDx
Premium

Jan 18, 2022

Sema4 to Acquire GeneDx for $623M

Jan 11, 2022

JP Morgan Healthcare Conference Day 1: Qiagen, Adaptive Bio, Guardant Health, Natera, Sema4

Jan 6, 2022

Dx IPO Window Widens in 2021 as COVID-19 Testing Provides Jumping Off Point
Premium

Nov 15, 2021

Sema4 Q3 Revenues Rise 12 Percent

Oct 8, 2021

BTIG Initiates Coverage of Sema4 With Buy Rating

Aug 16, 2021

Sema4 Reports 56 Percent Increase in Q2 Revenues

Jul 22, 2021

Sema4 Closes SPAC Deal With CM Life Sciences, Raising Approximately $500M
Premium

Jun 30, 2021

Even as Testing Demand Started to Wane, COVID-19 Drove IPOs in Dx Space in H1 2021
Premium

Jun 25, 2021

In Brief This Week: BioReference Laboratories, Tecan Group, Personal Genome Diagnostics, Sema4

Feb 10, 2021

Sema4 to Go Public Through Merger With Special Purpose Acquisition Company

Jan 13, 2021

JP Morgan Healthcare Conference, Day 2: Qiagen, LabCorp, Abbott, and More

Dec 3, 2020

In Brief This Week: Agilent, Unilabs, Caris Life Sciences, and More

Jul 29, 2020

Sema4 Raises $121M in Series C Financing Round

Jul 15, 2020

Sema4 Nabs New York State Approval for Cancer Somatic Sequencing Tests

Jun 1, 2020

Sema4 Forms Coronavirus Testing Alliance With Connecticut